Search

Emeritus membership

If you're a scientific researcher, physician, or healthcare-affiliated professional who's now retired or is close to retirement, you can join EHA at a reduced rate.

Read more

Travel Grants

Application for a travel grant closed on August 29

Travel grants are intended to support young investigators; therefore, applicants should be 36 years of age or young and are reserved for applicants from upper-middle, lower-middle, and low-income countries.

Read more

Chronic Myeloid Leukemia

The objective of this SWG is the cure of Chronic Myeloid Leukemia (CML) by cooperative research.

Read more

New at EHA 15: EHA-JSH Joint Symposium

On behalf of JSH Dr Toshiki Watanabe will speak about "Molecular pathogenesis of ATL". Dr Herman Einsele presents EHA with his lecture "New treatments strategies for EBV-associated LPD as a model for immunotherapy of virus-associated/induced tumors".

Read more

EHA-SLCH Hematology Tutorial on Myeloid Malignancies and MDS

Dates: February 8-9, 2019
Location: Colombo, Sri Lanka
Chairs: G Ossenkoppele, V Gunawardena, HW Goonasekera

After a successful first edition in 2017, EHA is organizing the second two-day tutorial in close collaboration with the Sri Lanka College of Haematologists (SLCH) on "Myeloid malignancies and MDS".…

Read more

EHA, in partnership with ISTH, award two fellows to support global educational opportunities

EHA and the International Society on Thrombosis and Hemostasis (ISTH) jointly awarded two joint ISTH-EHA Training Fellowships to Araci Rondon (The Netherlands) and Dianne van der Wal (Australia).

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more